Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03744910 · ClinicalTrials.gov registry record · Phase 3
Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
A Phase 3 study, sponsored by CSL Behring.
- Terminated
- Registry status
- Phase 3
- Development phase
- 194
- Enrollment target
NCT03744910 is a Phase 3 study that was terminated before completion, run by CSL Behring. The registered enrollment target is 194 participants.
The verdict
NCT03744910, a Phase 3 study, was terminated before completion, sponsored by CSL Behring.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 194 participants
- Enrollment target
Study Summary
This trial investigates the efficacy and safety of clazakizumab \[an anti-interleukin (IL)-6 monoclonal antibody (mAb)\] for the treatment of CABMR in recipients of a kidney transplant.
Interventions
- DRUG Physiologic saline solution
- BIOLOGICAL Clazakizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2019-10-14 |
| Est. Completion | 2024-04-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03744910
The ClinicalTrials.gov registry entry for NCT03744910 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Physiologic saline solution is the first listed.
NCT03744910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03744910 about?
NCT03744910 is a clinical study titled "Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients". This trial investigates the efficacy and safety of clazakizumab \[an anti-interleukin (IL)-6 monoclonal antibody (mAb)\] for the treatment of CABMR in recipients of a kidney transplant.
What is the current status of trial NCT03744910?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 194 participants. The study started on 2019-10-14. Estimated completion is 2024-04-08.
What interventions are being tested in trial NCT03744910?
The interventions under investigation include: Physiologic saline solution (DRUG), Clazakizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03744910?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.